Japan Alzheimer’s Disease Drugs Market Analysis

Japan Alzheimer’s Disease Drugs Market Analysis


$ 3999

Japan's Alzheimer’s disease drugs market was valued at $958 Mn in 2022 and is estimated to expand at a CAGR of 8.92% from 2022-30 and will reach $1899 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson., Novartis AG, Pfizer, Takeda Pharmaceutical, Chugai Pharmaceutical, Astellas Pharma, Otsuka Holdings Co, Shionogi & Co among others.

ID: IN10JPPH006 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Nandini Shah

Buy Now

Japan Alzheimer’s Disease Drugs Market Executive Summary

The Japan Alzheimer’s Disease Drugs market was valued at $958 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.92% from 2022 to 2030 and will reach $1899 Mn in 2030. Degeneration of brain nerve cells is a hallmark of Alzheimer's disease. It results in a decline in cognitive abilities such as memory, language, thinking, and behavior. Alzheimer's disease symptoms include depression, memory loss, lack of inhibitions, and problems thinking and reasoning. It is normally diagnosed through physical examinations, blood tests, brain imaging, mental status exams, and neuropsychological testing. Depending on the results, doctors prescribe different medications to reduce symptoms. Neurotransmitters, which are chemicals that convey messages between nerve cells in the brain, are affected by drugs for Alzheimer's disease.

More than 4.6 million people in Japan are affected by dementia. And it is predicted that as the population ages, this number will increase dramatically. Given that dementia affects at least 44 million individuals worldwide, the condition is a global health emergency that requires attention. Alzheimer's disease is a diagnosis that alters the lives of the patient, as well as their family and friends, but there is support and information available. Nobody has to deal with dementia or Alzheimer's alone.

japan alzheimers disease drugs market analysis

Market Dynamics

Market Growth Drivers

As the population in Japan continues to age, the incidence of Alzheimer's disease is expected to increase. This is a major driver of growth in the Alzheimer's drugs market in Japan. There has been a growing awareness of Alzheimer's disease in Japan, which has led to an increase in the number of diagnoses. This has resulted in an increased demand for Alzheimer's drugs. The Japanese government has taken steps to support the development of new Alzheimer's drugs, including providing funding for research and development. This has led to the introduction of new and more effective treatments. As healthcare expenditure in Japan continues to grow, more resources are being devoted to treating Alzheimer's disease. This has led to an increased demand for Alzheimer's drugs. Pharmaceutical companies are continuing to invest in the development of new Alzheimer's drugs, which are expected to drive growth in the market in the coming years.

Market Restraints

There is significant price pressure on Alzheimer's drugs in Japan, with the government and insurance companies seeking to reduce healthcare costs. This has resulted in lower prices for drugs and reduced profitability for pharmaceutical companies. There is strong competition from generic versions of Alzheimer's drugs in Japan, which can be significantly cheaper than branded drugs. This has led to a decrease in market share and revenue for some pharmaceutical companies. The regulatory environment in Japan can be challenging for pharmaceutical companies, with long approval times and strict requirements for clinical trials. This can slow down the development and launch of new Alzheimer's drugs. Despite significant investment in research and development, there is still a lack of effective treatments for Alzheimer's disease. Many drugs have shown only limited efficacy in clinical trials, which can be discouraging for pharmaceutical companies and investors.

Competitive Landscape

Key Players

  • Kyowa Kirin
  • Daiichi Sankyo Company
  • Eisai Co.
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Johnson and Johnson
  • F. Hoffmann-La Roche AG
  • Merck & Co.
  • Novartis AG
  • Pfizer
  • Takeda Pharmaceutical
  • Chugai Pharmaceutical
  • Astellas Pharma
  • Otsuka Holdings Co
  • Shionogi & Co

Healthcare Policies and Regulatory Landscape

In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) is responsible for the approval of drugs, medical devices, and regenerative medicine products. The PMDA assesses the safety, efficacy, and quality of new drugs before they can be marketed in Japan. In addition, the Japanese government has implemented a Health Technology Assessment (HTA) system to evaluate the cost-effectiveness of new drugs and medical devices. The HTA system assesses the clinical benefits, economic impact, and social implications of new drugs before they can be approved for reimbursement by the government. In terms of Alzheimer's disease, the Japanese government has implemented policies to encourage the development and approval of new drugs. For example, the Japanese government has implemented a fast-track approval system for innovative drugs, which can expedite the approval process for drugs that meet certain criteria.

Reimbursement Scenario

In Japan, the cost of healthcare is covered by the National Health Insurance (NHI) system. The NHI covers the cost of medical services and prescription drugs, including Alzheimer's drugs, for all residents of Japan. Under the NHI system, patients are required to pay a portion of the cost of treatment, known as the "co-payment." The co-payment for Alzheimer's drugs in Japan is typically around 30% of the cost of the drug, with the remaining 70% covered by the NHI. In addition to the NHI, there are other public and private insurance programs in Japan that provide coverage for healthcare costs, including Alzheimer's drugs. For example, the Long-term Care Insurance system provides coverage for the cost of long-term care for elderly individuals, including those with Alzheimer's disease.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alzheimer's Disease Drugs Market Segmentation

By Drug Class (Revenue, USD Billion)

  • Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
  • N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (Memantine)
  • Combination Drugs
  • Others (Lecanemab, Aducanumab)

Drug segmentation is the process of dividing a set of drugs into different categories or classes based on their pharmacological properties, therapeutic uses, and other characteristics. Here, Alzheimer’s Disease Drugs Market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Combination Drugs, and others like (Lecanemab, Aducanumab)

By Distribution Channel (Revenue, USD Billion)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Route of Administration

  • Oral
  • Transdermal
  • Intravenous

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 12 October 2023
Updated by: Jay Dalwadi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up